Following approval from Health Canada, Canveda imported 28 new strains of cannabis from a supplier in the Netherlands and proceeded with the cultivation of several of these new strains with a first harvest scheduled for April 2019. Cultivation of these new high-quality strains will provide Canveda with a multitude of different varieties of cannabis over the next few production cycles. The Canveda facility is now in full production and is expected to produce 1.2 million grams of high-quality cannabis flower over the next 12 months.
Additionally, Canveda is licenced to produce cannabis oils and capsules and has commenced the build-out of a small production laboratory expected to be operational by late Q2 2019. Once the initial two batches of oil have passed successful qualitative analysis, Canveda will request oils to be included in its medical sales licence. Once licenced, the production facility will operate temporarily pending completion of the much larger project in Owen Sound, Ontario.
“Receipt of the sale for medical purposes and standard processing licence is a very important step for our Canadian operations as they will allow us to develop the wholesale portion (B2B) of our business as well as new patient acquisition,” commented W. Scott Boyes, Chairman, President and CEO of MPX International. “We are eager to introduce our Salus-branded products into the Canadian medical cannabis space with a focus on deliveries to Canadian military veterans as a result of the support to Veterans offered by our Spartan Wellness subsidiary. Michael Arnkvarn, our Chief Operating Officer, Canada has multiple projects in his pipeline and further updates will be provided in due course.”
While MPX International is continuing to develop opportunities in the emerging global cannabis marketplace, the expectation is that the Company’s Canveda facility in Peterborough, amongst others, will be one of the first to generate significant revenues.